Alzheimer's disease (AD) is a major healthcare challenge with no curative treatment at
present. To address this challenge, we need a paradigm shift, where we focus on pre …

Background The paradigm shift towards earlier Alzheimer's disease (AD) stages and
personalized medicine creates new challenges for clinician-patient communication. We …

Background Both memory clinic professionals and patients see value in digital tools, yet
these hardly find their way to clinical practice. We explored the usability of a digital tool to …

Background The use of amyloid-PET in dementia workup is upcoming. At the same time,
amyloid-PET is costly and limitedly available. While the appropriate use criteria (AUC) aim …

Background Because of the shift towards earlier diagnosis of dementia and/or Alzheimer's
disease (AD), increasing numbers of individuals with subjective cognitive decline (SCD) and …

Background and Objectives Cognitive decline rates in Alzheimer disease (AD) vary greatly.
Disease-modifying treatments may alter cognitive decline trajectories, rendering their …

MRI segmentation offers the possibility to assess regional brain atrophy in a quantitative,
operator-independent manner. This approach has shown potential advantages when …

INTRODUCTION The development of biomarkers for Alzheimer's disease (AD) has allowed
researchers to increase sample homogeneity and test candidate treatments earlier in the …

Background: The experience of receiving psychiatric diagnoses is under researched. The
impact of how an individual receives a diagnosis of psychosis, as used in early intervention …

PURPOSE The Clinical Decision Support Innovation Collaborative (CDSiC) Trust and
Patient-centeredness Workgroup is charged with (1) supporting the design, implementation …